RECOVERY Collaborative Group – medRxiv 2021 (Posted: Feb 11, 2021) – No Peer Review Yet			
Study Design	Multicenter, RCT, open label, platform trial – **Severe COVID-19 – (1:1)**		
Location	UK – 131 hospitals		
Inclusion	Severely ill COVID-19 pneumonia (hypoxia with oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (CRP $\geq$ 75 mg/L)		
Exclusion	Hypersensitivity to tocilizumab, evidence of active tuberculosis infection or clear evidence of active bacterial, fungal, viral or other infection (besides COVID-19).		
Intervention	Tocilizumab 400 mg to 800 mg IV (second dose if no improvement after 12-24h)		
Control	Standard of care		
		Tocilizumab n=2022	**Control n=2094**
Primary/Secondary Outcomes			
Total: 28-day mortality		29%*	694 (33%)
Discharged alive from hospital within 28 days		54%**	47%
Receipt of invasive mechanical ventilation or death		33%***	38%
- Invasive mechanical ventilation		12%****	15%
- Death		27%****	31%
Comments: • p=0.0066 - ** p<0.0001 - *** p=0.0005 - ****p=0.01 Corticosteroids within 7 days prior to first dose was 82% in the toci arm and 82% in the control arm.			
Abbreviations: CRP, C-reactive protein; ICU, intensive care unit; IV, intravenously			